{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T05:54:55Z","timestamp":1792130095213,"version":"4.4.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.urolonc.2024.05.017","type":"journal-article","created":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T01:16:37Z","timestamp":1718414197000},"page":"374.e1-374.e10","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["CTLA4 genetic variants associated with urothelial bladder cancer susceptibility"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4411-8524","authenticated-orcid":false,"given":"Alexsandro","family":"Koike","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-6782","authenticated-orcid":false,"given":"Andr\u00e9a Name","family":"Colado Sim\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2851-6634","authenticated-orcid":false,"given":"Tainah Mendes","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4284-2084","authenticated-orcid":false,"given":"Kaue de Morais","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1929-4163","authenticated-orcid":false,"given":"Beatriz Rabello","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberson Henrique Gobanhi","family":"Gualberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1650-3575","authenticated-orcid":false,"given":"Daniel Felipe Piva","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2637-8998","authenticated-orcid":false,"given":"Guilherme Lerner","family":"Trigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6507-2839","authenticated-orcid":false,"given":"Edna Maria Vissoci","family":"Reiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4023-9548","authenticated-orcid":false,"given":"Marcell Alysson Batisti","family":"Lozovoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2024.05.017_bib0001","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.euf.2021.01.003","article-title":"Expression of programmed cell death ligand 1 as a predictive biomarker in metastatic urothelial carcinoma patients treated with first-line immune checkpoint inhibitors versus chemotherapy: A systematic review and meta-analysis","volume":"8","author":"Rizzo","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"1","key":"10.1016\/j.urolonc.2024.05.017_bib0002","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/cancers16010131","article-title":"Current landscape of immune checkpoint inhibitors for metastatic urothelial carcinoma: Is there a role for additional t-cell blockade?","volume":"16","author":"Ogbuji","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.urolonc.2024.05.017_bib0003","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.05.017_bib0004","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1182\/blood-2002-06-1668","article-title":"CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells","volume":"101","author":"Pistillo","year":"2002","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.urolonc.2024.05.017_bib0005","doi-asserted-by":"crossref","first-page":"6016","DOI":"10.3390\/cancers13236016","article-title":"Checkpoint inhibition in bladder cancer: Clinical expectations, current evidence, and proposal of future strategies based on a tumor-specific immunobiological approach","volume":"13","author":"Mancini","year":"2021","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.urolonc.2024.05.017_bib0006","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.3390\/cancers15102696","article-title":"Development and validation of blood-based predictive biomarkers for response to PD-1\/PD-L1 checkpoint inhibitors: Evidence of a universal systemic core of 3D immunogenetic profiling across multiple oncological indications","volume":"15","author":"Hunter","year":"2023","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.urolonc.2024.05.017_bib0007","doi-asserted-by":"crossref","first-page":"3596","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y","article-title":"A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells","volume":"29","author":"Magistrelli","year":"1999","journal-title":"Eur J Immunol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.05.017_bib0008","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/eji.201242529","article-title":"The soluble isoform of CTLA-4 as a regulator of T-cell responses","volume":"43","author":"Ward","year":"2013","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.urolonc.2024.05.017_bib0009","first-page":"1","article-title":"CTLA4 polymorphisms and de novo malignancy risk after renal transplantation in Chinese recipients","volume":"2015","author":"Guo","year":"2015","journal-title":"BioMed Res Int"},{"issue":"4","key":"10.1016\/j.urolonc.2024.05.017_bib0010","first-page":"485","article-title":"Association of CTLA4 and CD28 gene variants and circulating levels of their proteins in patients with breast cancer","volume":"30","author":"Isitmangil","year":"2016","journal-title":"In Vivo"},{"issue":"3","key":"10.1016\/j.urolonc.2024.05.017_bib0011","first-page":"173","article-title":"CTLA-4+49 A\/G polymorphism and the risk of lung cancer: A meta-analysis","volume":"24","author":"Wei","year":"2021","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"1","key":"10.1016\/j.urolonc.2024.05.017_bib0012","first-page":"414","article-title":"Association of five SNPs in cytotoxic T-lymphocyte antigen 4 and cancer susceptibility: Evidence from 67 studies","volume":"47","author":"Fang","year":"2018","journal-title":"Cell PhysiolBiochem"},{"key":"10.1016\/j.urolonc.2024.05.017_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.878507","article-title":"Comprehensive analysis of 29,464 cancer cases and 35,858 controls to investigate the effect of the cytotoxic t-lymphocyte antigen 4 gene rs231775 A\/G polymorphism on cancer risk","volume":"12","author":"Wan","year":"2022","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2024.05.017_bib0014","doi-asserted-by":"crossref","first-page":"828","DOI":"10.3109\/07357901003630934","article-title":"Circulating soluble CTLA4 (sCTLA4) is elevated in patients with breast cancer","volume":"28","author":"Erfani","year":"2010","journal-title":"Cancer Invest"},{"key":"10.1016\/j.urolonc.2024.05.017_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/10732748231152322","article-title":"Impact of age at diagnosis of bladder cancer on survival: asurveillance, epidemiology, and end results-based study 2004-2015","volume":"30","author":"Lin","year":"2023","journal-title":"Cancer Control"},{"issue":"2","key":"10.1016\/j.urolonc.2024.05.017_bib0016","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1007\/s13277-013-1152-x","article-title":"Association between the cytotoxic T-lymphocyte antigen 4 +49A\/G polymorphism and bladder cancer risk","volume":"35","author":"Wang","year":"2013","journal-title":"Tumor Biology"},{"issue":"10.1155\/2020\/8143158","key":"10.1016\/j.urolonc.2024.05.017_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/8143158","article-title":"CTLA-4 +49A\/G polymorphism increases the susceptibility to bladder cancer in chinese han participants: A case-control study","volume":"2020","author":"Mao","year":"2020","journal-title":"Dis Markers"},{"issue":"2","key":"10.1016\/j.urolonc.2024.05.017_bib0018","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s11033-013-2919-2","article-title":"Cytotoxic T lymphocyte antigen 4 (CTLA4) gene polymorphism with bladder cancer risk in north Indian population","volume":"41","author":"Jaiswal","year":"2014","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.urolonc.2024.05.017_bib0019","series-title":"International union against cancer. TNM classification of malignant tumors, ed. 8","first-page":"263","author":"Brierley","year":"2017"},{"issue":"1","key":"10.1016\/j.urolonc.2024.05.017_bib0020","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-Part B: Prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.05.017_bib0021","first-page":"S0022","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline","volume":"16","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2024.05.017_bib0022","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2217\/fon-2021-0841","article-title":"Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis","volume":"18","author":"Rizzo","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.urolonc.2024.05.017_bib0023","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-065X.2008.00662.x","article-title":"Control of peripheral T-cell tolerance andautoimmunity via the CTLA-4 and PD-1 pathways","volume":"224","author":"Fife","year":"2008","journal-title":"Immunol Rev"},{"issue":"4","key":"10.1016\/j.urolonc.2024.05.017_bib0024","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1074-7613(00)80366-0","article-title":"The emerging role of CTLA-4 as an immune attenuator","volume":"7","author":"Thompson","year":"1997","journal-title":"Immunity"},{"issue":"5","key":"10.1016\/j.urolonc.2024.05.017_bib0025","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s00280-019-03800-x","article-title":"Disruption of CTLA-4 expression on peripheral blood CD8\u202f+\u202fT cell enhances antitumor efficacy in bladder cancer","volume":"83","author":"Zhang","year":"2019","journal-title":"Cancer Chem Pharmacol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.05.017_bib0026","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1006\/cimm.2000.1649","article-title":"A native soluble form of CTLA-4","volume":"201","author":"Oaks","year":"2000","journal-title":"Cell Immunol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.05.017_bib0027","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1006\/mgme.2000.3015","article-title":"Molecular heterosis: A review","volume":"71","author":"Comings","year":"2000","journal-title":"Mol Gene Metabol"},{"issue":"40","key":"10.1016\/j.urolonc.2024.05.017_bib0028","doi-asserted-by":"crossref","first-page":"9657","DOI":"10.1523\/JNEUROSCI.0991-17.2017","article-title":"Overdominant effect of a CHRNA4 polymorphism on cingulo-opercular network activity and cognitive control","volume":"37","author":"Sadaghiani","year":"2017","journal-title":"J Neurosci"},{"key":"10.1016\/j.urolonc.2024.05.017_bib0029","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3389\/fendo.2020.00191","article-title":"Metformin and its benefits for various diseases","volume":"11","author":"Lv","year":"2020","journal-title":"Front Endocrinol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.05.017_bib0030","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00384-009-0806-z","article-title":"CTLA-4 +49A>G polymorphism is associated with the risk but not with the progression of colorectal cancer in Chinese","volume":"25","author":"Qi","year":"2010","journal-title":"Int J Colorectal Dis"},{"issue":"3","key":"10.1016\/j.urolonc.2024.05.017_bib0031","first-page":"188","article-title":"Strong association of CTLA-4 variation (CT60A\/G) and CTLA-4 haplotypes with predisposition of Iranians to head and neck cancer","volume":"9","author":"Erfani","year":"2012","journal-title":"Iran J Immunol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924004903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924004903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T06:48:35Z","timestamp":1725346115000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924004903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1078143924004903"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.05.017","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3709842\/v1","asserted-by":"object"}]},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CTLA4 genetic variants associated with urothelial bladder cancer susceptibility","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.05.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}